Study identification

PURI

https://redirect.ema.europa.eu/resource/38264

EU PAS number

EUPAS12795

Study ID

38264

Official title and acronym

Vargatef in 2nd-line therapy of advanced or metastatic adenocarcinoma of the lung (VARGADO)

DARWIN EU® study

No

Study countries

Germany

Study description

This observational study will investigate the efficacy and tolerability of Vargatef (Nintedanib) plus docetaxel in daily routine second-line treatment in patients with locally advanced, metastatic or locally recurrent NSCLC. Treatment with Vargatef in eligible NSCLC patients, for whom the treating physician has decided to initiate treatment with Vargatef in second line according to the local label, will be observed for up to 24 months. Survial follow-up will be done until the end of the study.

Study status

Ongoing
Research institutions and networks

Institutions

Contact details

Boehringer Ingelheim Pharma GmbH Boehringer Ingelheim Pharma GmbH

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim Pharma GmbH
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable